Articles tagged with Head and Neck Cancer
Researchers have found a dose-response relationship between IMRT volume and oral mucositis severity in head and neck cancer patients. Constricting IMRT dose can lessen toxic effects of treatment, reducing side effects for patients.
A clinical trial has found that a new treatment regimen combining radiation therapy with concurrent chemotherapy significantly increases the probability of survival for patients with recurrent squamous-cell head and neck cancer. The study showed improved one-year and two-year survival rates compared to standard chemotherapy treatment, ...
A new study from UNC Health Care found that whole-body PET/CT scanners are highly accurate in detecting the spread and recurrence of head and neck cancer. The scans can pick up cancer where none was thought to exist, allowing for more precise biopsies and treatment planning.
Researchers found that many cancer survivors make significant modifications in diet and physical activity after a diagnosis. Despite this, many continue to struggle with healthy behaviors, particularly males, less educated individuals, and those over 65.
A study analyzed data from 18 published studies on TP53 protein and mortality rates, finding selective reporting biases that may have fabricated strong associations. The authors caution that the findings highlight limitations of current research methods and call for more transparent reporting and better study design.
Researchers discover compound (-)-gossypol that targets Bcl-xL protein to induce programmed cell death in resistant cancer cells. The study suggests a potential treatment option for head and neck cancer patients who cannot undergo surgery.
A daily bioadhesive buccal tablet containing 50mg of miconazole has been shown to be as effective as a four-times-daily mouth gel in treating oropharyngeal candidiasis among head and neck cancer patients. This simpler treatment schedule may improve quality of life and increase patient compliance.
Researchers found that adding docetaxel to a combination chemotherapy regimen increased complete pathological response rates by 89% for patients with locally advanced squamous cell carcinoma of the head and neck. The treatment is expected to result in high survival rates, including 95% two-year and 90% five-year survival rates.
Researchers have discovered a compound derived from Chinese medicine that works to regulate a protein called Bcl-xL, which is overexpressed in cancer cells. The compound, (-)-gossypol, has been shown to induce programmed cell death in head and neck cancer cells resistant to chemotherapy.
A multicenter trial found that alpha-tocopherol supplementation increased the rate of developing a second primary cancer during treatment but reduced the risk after treatment ended. After 8 years, the proportion of participants free of a second primary cancer was similar in both groups.
Combination therapy of radiotherapy and cetuximab significantly improves loco-regional control, median survival, and overall survival rates in patients with loco-regionally advanced squamous cell carcinoma of the oropharynx, hypopharynx, or larynx. The treatment also showed minimal enhancement of toxicity compared to radiotherapy alone.
A new study links increased domestic production of betel quid to the incidence of head and neck cancer in Taiwan, with a strong cohort effect observed for men born between 1972-1980. The study suggests a correlation between betel quid usage and head and neck cancer incidence.
A study by Mitchell Machtay found that correcting anemia does not improve tumor control or survival in head and neck cancer patients. Despite increasing red blood cell count, erythropoietin did not enhance radiation therapy outcomes.
A study published in the Journal of Clinical Oncology found that smokers have a higher risk of death, disease recurrence, and poorer survival rates compared to non-smokers with head and neck cancer. Researchers highlighted the importance of tobacco cessation and moderation of alcohol use to improve quality of life and survival.
The University of Pittsburgh has received a $10 million federal grant to enhance the quality of life for head and neck cancer patients. Researchers will investigate genetic changes, intracellular signaling proteins, and new treatment strategies to reduce morbidity and mortality from head and neck cancer.
A study found that HPV DNA is present in tumors of HNSCC patients, suggesting a role for the virus in early cancer development. The findings support the idea that HNSCCs can be subdivided into two genetically distinct categories, one driven by environmental factors and the other by HPV infection.
A study published in Archives of Otolaryngology – Head and Neck Surgery found that 52% of employed head and neck cancer patients reported work-related disability after treatment. Chemotherapy, neck surgery, and pain were linked to increased disability risk.
A multicenter trial demonstrated that Taxotere in combination with cisplatin and 5-FU prolonged progression-free survival by 12.7 months compared to the standard treatment. Patients also showed significantly improved overall response rates, indicating a potential new paradigm for treating head and neck cancer.
A study identified four tumor gene expression patterns that may serve as biomarkers of prognosis for head and neck squamous cell cancer patients. The patterns were associated with different outcomes, including the worst outcome linked to epidermal growth factor pathway activation, and a tobacco exposure signature.
A new study found that infection with a high-risk type of human papillomavirus (HPV) in oral epithelial cells may be an independent risk factor for head and neck cancer. High-risk HPV types detected in oral exfoliated cells were predictive of high-risk HPV types in tumor tissue.
Researchers have discovered several protein profiles that are present more commonly in patients with HNSCC than in healthy smokers or control patients, enabling accurate diagnosis. The newly developed technology could potentially lead to the development of a reliable screening test for early detection and diagnosis of HNSCC.
A randomised controlled trial found that accelerated radiotherapy improved five-year tumour control by 10% compared to standard radiotherapy, with benefits also seen in patients with laryngeal cancer. The treatment was associated with a small increase in disease-specific survival, but also more acute morbidity.
A new trial has shown that faster radiotherapy can improve head and neck cancer treatment outcomes, with a 60-70% benefit in tumour control and better voice conservation. The study found that accelerated treatment was linked to high EGFR expression and good tumour differentiation.
UT MD Anderson Cancer Center receives $12 million SPORE grant to support head and neck cancer research, focusing on genetic susceptibility markers, angiogenic therapy, and other areas. The grant aims to accelerate progress in prevention, treatment, and early diagnosis of the disease.
Researchers at Ohio State University have developed an intensification therapy regimen that combines chemotherapy and radiation to treat advanced head and neck cancers. The treatment has shown promising results, with a significant increase in survival rates and minimal patient non-compliance.
A new study found that nearly a quarter of head and neck cancer patients continue to smoke, scoring lower on quality of life measures. Depression was also prevalent among these patients, with both smoking and depression associated with significantly poorer quality of life.
A study by Dr. Jennifer Grandis and colleagues identified a protein associated with lung cancer also expressed in head and neck cancer, leading to potential therapeutic strategies. The researchers found increased GRPR expression in head and neck cancer tissues compared to healthy controls.
Two new studies published in the Journal of the National Cancer Institute suggest that frequent tomato product consumption may reduce prostate cancer risk. Additionally, researchers found a possible role for the Ras gene in neuroblastoma regression and increased levels of GRP growth factor in head and neck cancers.
A study of 114 patients with primary head and neck cancers found that photodynamic therapy achieved an overall response rate of 91% after two years, with 85% showing complete tumor elimination. The treatment also produced high one- and two-year overall survival rates of 90% and 81%, respectively.
Researchers found that human papillomavirus (HPV) is associated with a subset of head and neck cancers, particularly those of the oropharynx, which are more likely to be caused by HPV. The study also showed improved survival rates among patients with HPV-positive tumors compared to those with HPV-negative tumors.
Scientists at Johns Hopkins have developed a novel approach for detecting cancer based on genetic mutations in mitochondrial DNA. The new test uses bodily fluids such as urine, saliva, and sputum to identify cancer-specific mutations.
A new study by Duke University Medical Center found that a combination of intensive, twice-daily radiation therapy and simultaneous chemotherapy can control cancer more frequently. The treatment resulted in a significant improvement in disease control and patient survival rates.
In a Phase II study combining ONYX-015 with standard chemotherapy, nine out of ten patients experienced tumor regressions greater than 50 percent, including two complete responses. Thirty percent of patients treated with ONYX-015 alone showed significant tumor regression.
Researchers demonstrate intratumoral delivery of the E1A gene, downregulating HER-2/neu expression and tumor responses. The study shows promise for using E1A gene therapy to treat a broad range of cancers.
Researchers found that genetic variations in enzymes metabolizing drugs contribute to cancer risk, particularly head and neck cancer. Individuals with certain enzyme genotypes or histories of environmental exposures are at increased risk for cancer.
A recent study by Johns Hopkins Medicine detected genetic mutations specific to cancer in blood samples of six patients with head and neck cancer. The presence of DNA alterations in the blood was associated with large, advanced tumors and poor outcomes, including increased mortality rates.